[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

Imaging will consist of administration of maximum 50 µg IV PentixaFor, labelled with 150 ±15 MBq of 68Ga, as bolus injection 60 ±15 minutes prior PET/CT

Inclusion criteria

• signed written informed consent
• male or female
• age ≥ 18 years
• patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I)
• SOC clinical follow-up at the cardiology department in CHUV.

Exclusion criteria

The presence of any one of the following exclusion criteria will lead to exclusion of the participant:

• absence of a signed written informed consent
• patients aged < 18 years
• claustrophobia
• myocardial ischemia in non-invasive perfusion test or coronarography in group II and III
• clinically unstable cardiovascular conditions, including:

• clinically unstable brady-tachyarrhythmia
• severe and symptomatic hypo- or hypertension with documented systolic blood pressure < 90 mmHg or ≥220 mmHg respectively
• cardiogenic shock.
• women who are pregnant or breast feeding
• intention to become pregnant during the course of the study in group II
• previous enrolment into the current study
• moderate to severe renal insufficiency (GFR < 45 mL/min/1,73 m2), with contra-indication to the administration of Gadolinium in group II and III
• enrollment of the investigator, his/her family members, employees and other dependent persons
• history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment
• insufficient knowledge of project language, inability to give consent or to follow procedures
• the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings